Synonym.bio

Site Inspections

Overview & More informations

Synonym.bio is a biotechnology company that is developing a new class of drugs to treat cancer. The company's lead drug candidate, SYNB1020, is a first-in-class, small molecule inhibitor of the BET bromodomain protein. BET bromodomains are epigenetic readers that play a key role in gene expression. SYNB1020 has shown promising anti-tumor activity in preclinical models of cancer, and the company is currently conducting a Phase 1 clinical trial to evaluate the safety and efficacy of the drug in patients with advanced solid tumors.

Synonym.bio was founded in 2015 by a team of scientists from the University of California, San Francisco. The company is headquartered in South San Francisco, California.

Synonym.bio has received funding from a variety of sources, including venture capital firms, angel investors, and government grants. The company's most recent funding round was a Series B financing that raised $50 million. This funding will be used to support the clinical development of SYNB1020 and to expand the company's pipeline of drug candidates.

Synonym.bio is a promising biotechnology company with a novel approach to treating cancer. The company's lead drug candidate, SYNB1020, has shown promising anti-tumor activity in preclinical models, and the company is currently conducting a Phase 1 clinical trial to evaluate the safety and efficacy of the drug in patients with advanced solid tumors.

Here are some additional details about synonym.bio:

• The company's website is https://synonym.bio.


• The company's CEO is Dr. David Marciano.


• The company has a team of experienced scientists and executives.


• The company is backed by a strong group of investors.


• The company is developing a promising pipeline of drug candidates.

Synonym.bio is a company to watch in the biotechnology space. The company's novel approach to treating cancer has the potential to make a significant impact on the lives of patients.

Domains Expiration Date Updated